Baloxavir Superior to Placebo for Alleviating Flu Symptoms

Share this content:
Baloxavir Superior to Placebo for Alleviating Flu Symptoms
Baloxavir Superior to Placebo for Alleviating Flu Symptoms

WEDNESDAY, Sept. 5, 2018 (HealthDay News) -- The selective inhibitor of influenza cap-dependent endonuclease, baloxavir marboxil, is superior to placebo for alleviating influenza symptoms, according to a study published in the Sept. 6 issue of the New England Journal of Medicine.

Frederick G. Hayden, M.D., from the University of Virginia School of Medicine in Charlottesville, and colleagues conducted two randomized trials involving otherwise healthy outpatients with acute uncomplicated influenza. After completion of a dose-ranging trial, a placebo- and oseltamivir-controlled trial of single, weight-based doses of baloxavir (40 or 80 mg) was conducted in patients aged 12 to 64 years.

The researchers found that the median time to alleviation of influenza symptoms was 23.4 to 28.2 hours shorter in the baloxavir versus the placebo group in the phase 2 trial (P < 0.05). In the phase 3 trial, which included 1,064 patients, the median time to alleviation of symptoms was 53.7 and 80.2 hours in the baloxavir and placebo groups, respectively (P < 0.001). The time to symptom alleviation was similar for baloxavir and oseltamivir. Greater reductions in viral load were seen with baloxavir versus placebo or oseltamivir one day after initiation of the regimen.

"Single-dose baloxavir was without evident safety concerns, was superior to placebo in alleviating influenza symptoms, and was superior to both oseltamivir and placebo in reducing the viral load one day after initiation of the trial regimen in patients with uncomplicated influenza," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Shionogi, which manufactures baloxavir and funded the study.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

8 More U.S. Communities to Be Assessed for PFAS Toxin Exposure

8 More U.S. Communities to Be Assessed for ...

Assessments will lay groundwork for future study of the health effects of perfluoroalkyl, polyfluoroalkyl

FDA Advances Regulation to Ensure Sunscreen Safety, Efficacy

FDA Advances Regulation to Ensure Sunscreen Safety, Efficacy

Proposed rule will help consumers better understand what the sunscreens they are buying can actually do

U.S. Agencies Probing Johnson  Johnson Over Asbestos in Talc

U.S. Agencies Probing Johnson &amp; Johnson Over Asbestos ...

Company has faced lawsuits linking its body powders with ovarian cancer or mesothelioma

is free, fast, and customized just for you!




Already a member?

Sign In Now »